Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 2,562 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the sale, the chief financial officer now owns 75,557 shares of the company's stock, valued at approximately $10,457,844.37. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, March 17th, Michael Burkes Brophy sold 792 shares of Natera stock. The shares were sold at an average price of $146.04, for a total transaction of $115,663.68.
- On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76.
- On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $719,046.45.
- On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total value of $333,067.60.
- On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54.
- On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.
- On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.
Natera Stock Performance
Shares of NASDAQ NTRA opened at $140.65 on Wednesday. The stock has a market capitalization of $19.01 billion, a P/E ratio of -79.91 and a beta of 1.80. The firm's 50-day moving average price is $158.72 and its two-hundred day moving average price is $151.35. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.
Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the company. Barclays initiated coverage on Natera in a research report on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 price objective on the stock. Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. JPMorgan Chase & Co. upped their price target on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. BTIG Research reiterated a "buy" rating on shares of Natera in a research note on Friday, February 28th. Finally, Robert W. Baird upped their target price on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $178.12.
Check Out Our Latest Analysis on Natera
Institutional Trading of Natera
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after acquiring an additional 879,463 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after buying an additional 2,036,396 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Natera by 15.7% in the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after buying an additional 439,778 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Natera by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock valued at $355,809,000 after buying an additional 142,201 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
